163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; pp. S196 - S197
Main Authors Curigliano, G., Dunton, K., Rosenlund, M., Janek, M., Cathcart, J., Liu, Y., Fasching, P.A., Iwata, H.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.05.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2022.03.182